ArticleBJU international2014
Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis.
Article in BJU international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.
- Penile cancer: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.ESMO open · 2024Guideline
- A phase II trial of cabazitaxel as second line chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis.The Journal of international medical research · 2019Trial
- Assessment of EGFR and HER2 expression in penile cancer as potential therapeutic targets.Virchows Archiv : an international journal of pathology · 2026Article
- Neoadjuvant Treatment for Penile Cancer: A Systematic Review of Contemporary Evidence.Cancers · 2026Review
- [Treatment options in rare urological tumors: potential of molecular tumor boards].Urologie (Heidelberg, Germany) · 2026Review
- Systemic Chemotherapy in Penile Squamous Cell Carcinoma: Mechanisms, Clinical Applications, and Evidence-Based Regimens.Cancers · 2025Review
- [Personalized systemic therapy of penile cancer: molecular targets and new therapeutic horizons].Urologie (Heidelberg, Germany) · 2025Review
- Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis.Experimental hematology & oncology · 2025Article
- Evidence-Based Recommendations on the Use of Immunotherapies and Monoclonal Antibodies in the Treatment of Male Reproductive Cancers.Current oncology (Toronto, Ont.) · 2025Review
- Molecular characterization of metastatic penile squamous cell carcinoma in developing countries and its impact on clinical outcomes: LACOG 2018 translational study.The oncologist · 2025Article
- Real-World Outcomes in Patients with Advanced Penile Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Single Institution Experience.Journal of immunotherapy and precision oncology · 2025Article
- Mutational landscape of epidermoid carcinoma of the penis in a Brazilian cohort.Exploration of targeted anti-tumor therapy · 2025Article
- Review
- Treatment approaches in advanced penile cancer: targeted therapies and immunotherapy.Frontiers in oncology · 2024Review
- Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin.International journal of molecular sciences · 2023Article
- Clinical Profile and Predictors of Survival in Carcinoma Penis Patients.Current oncology (Toronto, Ont.) · 2023Article
- Conversion therapy for advanced penile cancer with tislelizumab combined with chemotherapy: A case report and review of literature.World journal of clinical cases · 2022Article
- Penile cancer: Updates in systemic therapy.Asian journal of urology · 2022Review
- miRNA and mRNA Expression Profiles Associated with Lymph Node Metastasis and Prognosis in Penile Carcinoma.International journal of molecular sciences · 2022Article
- Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo evaluate the safety and efficacy of epidermal growth factor receptor (EGFR)-targeted therapy in patients with advanced penile or scrotal cancer. PATIENTS AND
methodsWe retrospectively reviewed the charts of patients with penile or scrotal squamous cell carcinoma who had visited our tertiary cancer centre between 2002 and 2009, including their subsequent treatment and follow-up. We collected details of EGFR-targeted therapy and clinical outcomes. Treatment-associated time-to-disease-progression (TTP), overall survival (OS), responses to therapy and toxicity were evaluated.
resultsA total of 24 patients had received EGFR-targeted therapies, including cetuximab, erlotinib and gefitinib. The most common treatment given (to 67% of patients) was cetuximab combined with one or more cytotoxic drugs. The most common adverse effect was skin rash (71%). The median (range) TTP and OS were 11.3 (1-40) and 29.6 (2-205) weeks, respectively. The OS time for patients with visceral or bone metastases was significantly shorter than it was for those without (24.7 vs 49.9 weeks, P = 0.013). Among 17 patients treated with cetuximab alone or in combination with cisplatin, there were four partial responses (23.5%) including two patients with apparently chemotherapy-resistant tumours.
conclusionsOur results suggest that cetuximab has antitumour activity in metastatic penile cancer, and may enhance the effect of cisplatin-based chemotherapy. Prospective studies of EGFR-targeted therapies in men with these tumours are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.